CN1234373C - 含嗜酸乳杆菌的药物制剂及制备方法 - Google Patents
含嗜酸乳杆菌的药物制剂及制备方法 Download PDFInfo
- Publication number
- CN1234373C CN1234373C CNB001254693A CN00125469A CN1234373C CN 1234373 C CN1234373 C CN 1234373C CN B001254693 A CNB001254693 A CN B001254693A CN 00125469 A CN00125469 A CN 00125469A CN 1234373 C CN1234373 C CN 1234373C
- Authority
- CN
- China
- Prior art keywords
- bacillus acidophilus
- preparation
- vagina
- strain
- lactobacillus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 240000001046 Lactobacillus acidophilus Species 0.000 title claims abstract description 86
- 235000013956 Lactobacillus acidophilus Nutrition 0.000 title claims abstract description 84
- 238000002360 preparation method Methods 0.000 title claims abstract description 39
- 229940039695 lactobacillus acidophilus Drugs 0.000 title abstract description 7
- 210000001215 vagina Anatomy 0.000 claims abstract description 84
- 239000007788 liquid Substances 0.000 claims abstract description 26
- 239000000546 pharmaceutical excipient Substances 0.000 claims abstract description 12
- 239000007921 spray Substances 0.000 claims abstract description 7
- 239000007787 solid Substances 0.000 claims abstract description 6
- 239000006071 cream Substances 0.000 claims abstract description 3
- 239000000829 suppository Substances 0.000 claims abstract description 3
- 241000894006 Bacteria Species 0.000 claims description 60
- 230000001580 bacterial effect Effects 0.000 claims description 21
- 229920001817 Agar Polymers 0.000 claims description 13
- 239000008272 agar Substances 0.000 claims description 13
- 238000000034 method Methods 0.000 claims description 13
- 239000003826 tablet Substances 0.000 claims description 12
- 238000000855 fermentation Methods 0.000 claims description 11
- 230000004151 fermentation Effects 0.000 claims description 11
- 239000003814 drug Substances 0.000 claims description 10
- 239000001963 growth medium Substances 0.000 claims description 10
- 239000000843 powder Substances 0.000 claims description 9
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 8
- 210000003756 cervix mucus Anatomy 0.000 claims description 7
- 239000002609 medium Substances 0.000 claims description 7
- 230000008859 change Effects 0.000 claims description 6
- 235000013336 milk Nutrition 0.000 claims description 6
- 239000008267 milk Substances 0.000 claims description 6
- 210000004080 milk Anatomy 0.000 claims description 6
- 238000000746 purification Methods 0.000 claims description 5
- 235000015193 tomato juice Nutrition 0.000 claims description 5
- 201000000077 Cysticercosis Diseases 0.000 claims description 4
- 229940124531 pharmaceutical excipient Drugs 0.000 claims description 4
- 208000004441 taeniasis Diseases 0.000 claims description 4
- 239000002674 ointment Substances 0.000 claims description 3
- 238000000926 separation method Methods 0.000 claims description 3
- 235000015278 beef Nutrition 0.000 claims description 2
- 239000002775 capsule Substances 0.000 claims description 2
- 239000013583 drug formulation Substances 0.000 claims description 2
- 238000004108 freeze drying Methods 0.000 claims description 2
- 238000011081 inoculation Methods 0.000 claims description 2
- 239000002932 luster Substances 0.000 claims description 2
- 239000013521 mastic Substances 0.000 claims description 2
- 230000008569 process Effects 0.000 claims description 2
- 230000028327 secretion Effects 0.000 claims description 2
- 241000894007 species Species 0.000 claims description 2
- 238000005303 weighing Methods 0.000 claims description 2
- 206010018612 Gonorrhoea Diseases 0.000 abstract description 6
- 208000001786 gonorrhea Diseases 0.000 abstract description 6
- 208000015181 infectious disease Diseases 0.000 abstract description 4
- 239000006072 paste Substances 0.000 abstract 1
- 208000013464 vaginal disease Diseases 0.000 abstract 1
- 241000186660 Lactobacillus Species 0.000 description 48
- 241000222122 Candida albicans Species 0.000 description 46
- 229940095731 candida albicans Drugs 0.000 description 45
- 241000588724 Escherichia coli Species 0.000 description 44
- 229940039696 lactobacillus Drugs 0.000 description 43
- 238000012360 testing method Methods 0.000 description 34
- 241000700159 Rattus Species 0.000 description 33
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 22
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 18
- 239000007938 effervescent tablet Substances 0.000 description 18
- 241001465754 Metazoa Species 0.000 description 17
- 239000000853 adhesive Substances 0.000 description 16
- 230000001070 adhesive effect Effects 0.000 description 16
- 230000000844 anti-bacterial effect Effects 0.000 description 13
- 230000037396 body weight Effects 0.000 description 13
- 210000002919 epithelial cell Anatomy 0.000 description 12
- 241000588653 Neisseria Species 0.000 description 11
- 244000052616 bacterial pathogen Species 0.000 description 11
- 239000004310 lactic acid Substances 0.000 description 11
- 235000014655 lactic acid Nutrition 0.000 description 11
- 230000000694 effects Effects 0.000 description 10
- 239000000463 material Substances 0.000 description 9
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 8
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 8
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 8
- 206010046914 Vaginal infection Diseases 0.000 description 8
- 235000009508 confectionery Nutrition 0.000 description 8
- 201000010099 disease Diseases 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- 210000000981 epithelium Anatomy 0.000 description 8
- 210000004877 mucosa Anatomy 0.000 description 8
- 241000251468 Actinopterygii Species 0.000 description 7
- 230000006399 behavior Effects 0.000 description 7
- 238000005842 biochemical reaction Methods 0.000 description 7
- 238000006243 chemical reaction Methods 0.000 description 7
- 238000002156 mixing Methods 0.000 description 7
- FRXSZNDVFUDTIR-UHFFFAOYSA-N 6-methoxy-1,2,3,4-tetrahydroquinoline Chemical compound N1CCCC2=CC(OC)=CC=C21 FRXSZNDVFUDTIR-UHFFFAOYSA-N 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
- 239000000725 suspension Substances 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 241000233866 Fungi Species 0.000 description 5
- 230000005856 abnormality Effects 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 238000004043 dyeing Methods 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 4
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 4
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 4
- 229920000742 Cotton Polymers 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 229930182566 Gentamicin Natural products 0.000 description 4
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 4
- 229920002527 Glycogen Polymers 0.000 description 4
- 229930193140 Neomycin Natural products 0.000 description 4
- 235000008331 Pinus X rigitaeda Nutrition 0.000 description 4
- 235000011613 Pinus brutia Nutrition 0.000 description 4
- 241000018646 Pinus brutia Species 0.000 description 4
- 241000219000 Populus Species 0.000 description 4
- 240000000111 Saccharum officinarum Species 0.000 description 4
- 235000007201 Saccharum officinarum Nutrition 0.000 description 4
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
- 239000004098 Tetracycline Substances 0.000 description 4
- 201000008100 Vaginitis Diseases 0.000 description 4
- 235000009754 Vitis X bourquina Nutrition 0.000 description 4
- 235000012333 Vitis X labruscana Nutrition 0.000 description 4
- 240000006365 Vitis vinifera Species 0.000 description 4
- 235000014787 Vitis vinifera Nutrition 0.000 description 4
- 229960004821 amikacin Drugs 0.000 description 4
- LKCWBDHBTVXHDL-RMDFUYIESA-N amikacin Chemical compound O([C@@H]1[C@@H](N)C[C@H]([C@@H]([C@H]1O)O[C@@H]1[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O1)O)NC(=O)[C@@H](O)CCN)[C@H]1O[C@H](CN)[C@@H](O)[C@H](O)[C@H]1O LKCWBDHBTVXHDL-RMDFUYIESA-N 0.000 description 4
- 229960000723 ampicillin Drugs 0.000 description 4
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 4
- 230000008485 antagonism Effects 0.000 description 4
- 150000003851 azoles Chemical class 0.000 description 4
- 230000033228 biological regulation Effects 0.000 description 4
- 238000009395 breeding Methods 0.000 description 4
- 230000001488 breeding effect Effects 0.000 description 4
- 229960001668 cefuroxime Drugs 0.000 description 4
- JFPVXVDWJQMJEE-IZRZKJBUSA-N cefuroxime Chemical compound N([C@@H]1C(N2C(=C(COC(N)=O)CS[C@@H]21)C(O)=O)=O)C(=O)\C(=N/OC)C1=CC=CO1 JFPVXVDWJQMJEE-IZRZKJBUSA-N 0.000 description 4
- 229960005091 chloramphenicol Drugs 0.000 description 4
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 4
- 150000002016 disaccharides Chemical class 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 235000013399 edible fruits Nutrition 0.000 description 4
- 229960003276 erythromycin Drugs 0.000 description 4
- PLHJDBGFXBMTGZ-WEVVVXLNSA-N furazolidone Chemical compound O1C([N+](=O)[O-])=CC=C1\C=N\N1C(=O)OCC1 PLHJDBGFXBMTGZ-WEVVVXLNSA-N 0.000 description 4
- 229960001625 furazolidone Drugs 0.000 description 4
- 229960002518 gentamicin Drugs 0.000 description 4
- 239000003292 glue Substances 0.000 description 4
- 229940096919 glycogen Drugs 0.000 description 4
- 229930182470 glycoside Natural products 0.000 description 4
- 150000002338 glycosides Chemical class 0.000 description 4
- 238000010562 histological examination Methods 0.000 description 4
- 235000012907 honey Nutrition 0.000 description 4
- 238000007689 inspection Methods 0.000 description 4
- 239000002207 metabolite Substances 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 229960004927 neomycin Drugs 0.000 description 4
- 230000001717 pathogenic effect Effects 0.000 description 4
- 239000002504 physiological saline solution Substances 0.000 description 4
- FGIUAXJPYTZDNR-UHFFFAOYSA-N potassium nitrate Chemical compound [K+].[O-][N+]([O-])=O FGIUAXJPYTZDNR-UHFFFAOYSA-N 0.000 description 4
- 150000003839 salts Chemical class 0.000 description 4
- 239000013049 sediment Substances 0.000 description 4
- 239000006152 selective media Substances 0.000 description 4
- 239000000377 silicon dioxide Substances 0.000 description 4
- 235000012239 silicon dioxide Nutrition 0.000 description 4
- 229960002180 tetracycline Drugs 0.000 description 4
- 229930101283 tetracycline Natural products 0.000 description 4
- 235000019364 tetracycline Nutrition 0.000 description 4
- 150000003522 tetracyclines Chemical class 0.000 description 4
- 241000283690 Bos taurus Species 0.000 description 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- 229930195725 Mannitol Natural products 0.000 description 3
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 230000002378 acidificating effect Effects 0.000 description 3
- 244000309466 calf Species 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000012531 culture fluid Substances 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 210000004392 genitalia Anatomy 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 235000019359 magnesium stearate Nutrition 0.000 description 3
- 239000000594 mannitol Substances 0.000 description 3
- 235000010355 mannitol Nutrition 0.000 description 3
- 230000000813 microbial effect Effects 0.000 description 3
- 244000000010 microbial pathogen Species 0.000 description 3
- 244000005700 microbiome Species 0.000 description 3
- 239000008108 microcrystalline cellulose Substances 0.000 description 3
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 3
- 229940016286 microcrystalline cellulose Drugs 0.000 description 3
- 229920003023 plastic Polymers 0.000 description 3
- 239000004033 plastic Substances 0.000 description 3
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 3
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 3
- 230000001681 protective effect Effects 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- 238000010998 test method Methods 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 231100000331 toxic Toxicity 0.000 description 3
- 230000002588 toxic effect Effects 0.000 description 3
- 235000019786 weight gain Nutrition 0.000 description 3
- 235000013618 yogurt Nutrition 0.000 description 3
- 102000040350 B family Human genes 0.000 description 2
- 108091072128 B family Proteins 0.000 description 2
- 241000606125 Bacteroides Species 0.000 description 2
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 2
- QWIZNVHXZXRPDR-UHFFFAOYSA-N D-melezitose Natural products O1C(CO)C(O)C(O)C(O)C1OC1C(O)C(CO)OC1(CO)OC1OC(CO)C(O)C(O)C1O QWIZNVHXZXRPDR-UHFFFAOYSA-N 0.000 description 2
- HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 2
- 206010020565 Hyperaemia Diseases 0.000 description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
- 241001147746 Lactobacillus delbrueckii subsp. lactis Species 0.000 description 2
- 241000186869 Lactobacillus salivarius Species 0.000 description 2
- 241000204031 Mycoplasma Species 0.000 description 2
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 241000194017 Streptococcus Species 0.000 description 2
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 2
- 229930003268 Vitamin C Natural products 0.000 description 2
- 230000001464 adherent effect Effects 0.000 description 2
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 2
- 239000005030 aluminium foil Substances 0.000 description 2
- 229910021529 ammonia Inorganic materials 0.000 description 2
- 230000002547 anomalous effect Effects 0.000 description 2
- 230000003042 antagnostic effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 229910000019 calcium carbonate Inorganic materials 0.000 description 2
- 239000001569 carbon dioxide Substances 0.000 description 2
- 229910002092 carbon dioxide Inorganic materials 0.000 description 2
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 230000002860 competitive effect Effects 0.000 description 2
- 238000009792 diffusion process Methods 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 210000003608 fece Anatomy 0.000 description 2
- 235000013922 glutamic acid Nutrition 0.000 description 2
- 239000004220 glutamic acid Substances 0.000 description 2
- 230000003118 histopathologic effect Effects 0.000 description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
- 229960003943 hypromellose Drugs 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 239000002085 irritant Substances 0.000 description 2
- 231100000021 irritant Toxicity 0.000 description 2
- 231100000682 maximum tolerated dose Toxicity 0.000 description 2
- QWIZNVHXZXRPDR-WSCXOGSTSA-N melezitose Chemical compound O([C@@]1(O[C@@H]([C@H]([C@@H]1O[C@@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O)CO)CO)[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O QWIZNVHXZXRPDR-WSCXOGSTSA-N 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 231100000915 pathological change Toxicity 0.000 description 2
- 230000036285 pathological change Effects 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 238000004321 preservation Methods 0.000 description 2
- 239000006041 probiotic Substances 0.000 description 2
- 230000000529 probiotic effect Effects 0.000 description 2
- 235000018291 probiotics Nutrition 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000005070 sampling Methods 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000011975 tartaric acid Substances 0.000 description 2
- 235000002906 tartaric acid Nutrition 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 231100000820 toxicity test Toxicity 0.000 description 2
- 229940099259 vaseline Drugs 0.000 description 2
- 210000001835 viscera Anatomy 0.000 description 2
- 239000011718 vitamin C Substances 0.000 description 2
- 235000019154 vitamin C Nutrition 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- XWBADQOPXPRKBX-FMIVXFBMSA-N 1-n,1-n-diethyl-4-n-[6-methoxy-2-[(e)-2-(4-nitrophenyl)ethenyl]quinolin-4-yl]pentane-1,4-diamine Chemical compound N=1C2=CC=C(OC)C=C2C(NC(C)CCCN(CC)CC)=CC=1\C=C\C1=CC=C([N+]([O-])=O)C=C1 XWBADQOPXPRKBX-FMIVXFBMSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 206010007134 Candida infections Diseases 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 241000186216 Corynebacterium Species 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 241000305071 Enterobacterales Species 0.000 description 1
- 241000194032 Enterococcus faecalis Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 241000186840 Lactobacillus fermentum Species 0.000 description 1
- 229920000881 Modified starch Polymers 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 241000269799 Perca fluviatilis Species 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- 241000191940 Staphylococcus Species 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 241000191963 Staphylococcus epidermidis Species 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000002924 anti-infective effect Effects 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 239000003716 antitrichomonal agent Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 description 1
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 150000001510 aspartic acids Chemical class 0.000 description 1
- 230000010065 bacterial adhesion Effects 0.000 description 1
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
- 239000004327 boric acid Substances 0.000 description 1
- 235000010338 boric acid Nutrition 0.000 description 1
- 239000012267 brine Substances 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- 229940060243 calcium carbonate 60 mg Drugs 0.000 description 1
- 201000003984 candidiasis Diseases 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 230000004956 cell adhesive effect Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 210000003679 cervix uteri Anatomy 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 230000009514 concussion Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 239000002526 disodium citrate Substances 0.000 description 1
- 235000019262 disodium citrate Nutrition 0.000 description 1
- CEYULKASIQJZGP-UHFFFAOYSA-L disodium;2-(carboxymethyl)-2-hydroxybutanedioate Chemical compound [Na+].[Na+].[O-]C(=O)CC(O)(C(=O)O)CC([O-])=O CEYULKASIQJZGP-UHFFFAOYSA-L 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229960001031 glucose Drugs 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- 239000000745 gonadal hormone Substances 0.000 description 1
- 239000003163 gonadal steroid hormone Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 230000001861 immunosuppressant effect Effects 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 229960001375 lactose Drugs 0.000 description 1
- JCQLYHFGKNRPGE-FCVZTGTOSA-N lactulose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 JCQLYHFGKNRPGE-FCVZTGTOSA-N 0.000 description 1
- 229960000511 lactulose Drugs 0.000 description 1
- -1 lanoline Substances 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 238000009630 liquid culture Methods 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 229960001855 mannitol Drugs 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 210000003622 mature neutrocyte Anatomy 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- HWPKGOGLCKPRLZ-UHFFFAOYSA-M monosodium citrate Chemical compound [Na+].OC(=O)CC(O)(C([O-])=O)CC(O)=O HWPKGOGLCKPRLZ-UHFFFAOYSA-M 0.000 description 1
- 239000002524 monosodium citrate Substances 0.000 description 1
- 235000018342 monosodium citrate Nutrition 0.000 description 1
- 239000006916 nutrient agar Substances 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 230000027758 ovulation cycle Effects 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000003223 protective agent Substances 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
- 238000012109 statistical procedure Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000004575 stone Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 206010046901 vaginal discharge Diseases 0.000 description 1
Landscapes
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Description
VEC编号 | 粘附细菌数(个/VEC) | VEC编号 | 粘附细菌数(个/VEC) | VEC编号 | 粘附细菌数(个/VEC) |
1 | 132 | 18 | 92 | 35 | 85 |
2 | 113 | 19 | 120 | 36 | 123 |
3 | 74 | 20 | 89 | 37 | 144 |
4 | 149 | 21 | 65 | 38 | 131 |
5 | 186 | 22 | 78 | 39 | 156 |
6 | 118 | 23 | 158 | 40 | 98 |
7 | 111 | 24 | 75 | 41 | 143 |
8 | 63 | 25 | 126 | 42 | 125 |
9 | 84 | 26 | 118 | 43 | 95 |
10 | 89 | 27 | 109 | 44 | 194 |
11 | 94 | 28 | 138 | 45 | 88 |
12 | 118 | 29 | 80 | 46 | 155 |
13 | 119 | 30 | 128 | 47 | 178 |
14 | 125 | 31 | 74 | 48 | 122 |
15 | 90 | 32 | 77 | 49 | 167 |
16 | 120 | 33 | 50 | 50 | 133 |
17 | 129 | 34 | 62 | X±S | 113.8±33.69 |
菌株 | 大肠杆菌44113粘附数/VEC(X±S) | 白色念珠菌10231粘附数/VEC(X±S) | 统计处理 |
大肠杆菌44113 | 157.14±54.06 | ||
酸乳杆菌SL9404+大肠杆菌44113 | 118.13±49.24 | P<0.01 | |
德氏乳杆菌+大肠杆菌44113 | 147.78±45.12 | P>0.05 | |
白色念珠菌10321 | 31.84±11.65 | ||
嗜乳酸杆菌S9404+白色念珠菌10231 | 9.76±5.94 | P<0.01 | |
德氏乳杆菌+白色念珠菌10231 | 15.66±8.45 | P<0.01 |
菌株 | 大肠杆菌44113粘附数/VEC-(X±S) | 白色念珠菌10231粘附数/VEC(X±S) | 统计处理 |
大肠杆菌44113 | 267.22±97.80 | P<0.01 | |
嗜酸乳杆菌SL9404+大肠杆菌44113 | 125.26±51.64 | ||
白色念珠菌10231 | 29.24±8.45 | P<0.01 | |
嗜酸乳杆菌SL9404+白色念珠菌10231 | 19.54±10.24 |
菌株 | 大肠杆菌44113粘附数/VEC(X±S) | 白色念珠菌10231粘附数/VEC(X±S) | 统计处理 |
大肠杆菌44113 | 180.7±252.20 | P<0.01 | |
大肠杆菌44113+嗜酸乳杆菌SL9404 | 134.18±40.63 | ||
白色念珠菌10231 | 29.24 ±8.85 | 0.01<P<0.05 | |
白色念珠菌10231+嗜酸乳杆菌SL9404 | 24.40±11.36 |
组别 | 不同培养时间的活菌数(CFU/ml)Log值 | ||||||
0小时 | 12小时 | 24小时 | 48小时 | 72小时 | 96小时 | ||
试验组 | SL9404+***29403 | 5.91653.3979 | 8.35023.8692 | 8.8209<1 | 8.4983<1 | 8.0253<1 | |
SL9404+大肠杆菌44113 | 5.91653.7782 | 8.25778.8727 | 8.83958.7404 | 8.9004<5 | 8.7308<1 | ||
SL9404+白色念珠菌10231 | 5.91653.7782 | 8.32017.6821 | 8.57757.8420 | 8.77457.7474 | 8.80287.8921 | 8.75597.9731 | |
对照组 | ***29403 | 3.3979 | 3.8865 | 3.6990 | <1 | <1 | |
大肠杆菌44113 | 3.7782 | 8.8882 | 8.8176 | 8.8987 | 8.4409 | ||
白色念珠菌10231 | 3.7782 | 7.8481 | 8.1614 | 8.1903 | 8.4314 | 8.2041 | |
嗜酸乳杆菌SL9404 | 5.9165 | 8.4100 | 8.7752 | 8.2455 | 7.8722 | 7.1303 |
时间(天) | 未处理组体重(g) | 赋形剂体重(g) | 0.25×107CFU/g/只体重(g) | 0.25×109CFU/g/只体重(g) |
D0D2D4D6D8D10D12D14 | 219.7±11.1221.8±13.7224.9±14.1230.4±12.9231.2±13.0233.2±9.96235.2±9.66238.7±10.1 | 220.2±8.2223.9±7.1229.2±6.2237.3±8.6240.4±11.1246.7±14.4250.6±14.6253.0±14.5 | 220.0±8.9228.8±5.3236.3±7.3247.9±8.7250.9±7.8259.1±8.7259.5±10.7260.9±10.8 | 219.3±7.7223.4±8.9232.8±11.7244.5±12.8250.5±14.2255.5±14.2251.0±16.3254.3±15.5 |
检查项目 | 9404株(原代) | 9404株(30代) |
生长特性 | (1)需氧或厌氧环境中均可生长(2)在MRS琼脂上生长为浅淡黄色、中央突起圆形菌落直径约0.5-1mm。 | (1)需氧或厌氧环境中均可生长(2)在MRS琼脂上生长为浅淡黄色、中央突起圆形菌落直径约0.5-1mm。 |
染色镜检 | 革兰氏染色阳性菌体呈短杆形,散在或成对,成短链排列。菌体大小约0.5-0.8μm×1.5-3μm | 革兰氏染色阳性菌体呈短杆形,散在或成对,成短链排列。菌体大小约0.5-0.8μm×1-2.5μm |
生化反应 | 阿木鼠核葡甘果半蔗麦拉 李 萄露 乳 芽伯糖糖糖糖糖糖糖糖糖糖- - - + + + + + + + | 阿木鼠核葡甘果半蔗麦拉 李 萄露 乳 芽伯糖糖糖糖糖糖糖糖糖糖- - - + + + + + + + |
纤乳蕈蜜棉松可淀甘山七维 二子三溶 露梨叶二 糖糖糖性粉醇醇苷糖糖糖+ + + - - + - + + + | 纤乳蕈蜜棉松可淀甘山七维 二子三溶 露梨叶二 糖糖糖性粉醇醇苷糖糖糖+ + + - - + - + + + | |
水明硝还牛触杨胶酸 奶素液盐原凝化 固酶+ - - + - | 水明硝还牛触杨胶酸奶素液盐原凝化 固酶+ - - + - | |
药敏试验 | 丁胺卡那霉素 R 四环素 S庆大霉素 R 红霉素 S链霉素 R 多粘菌素B R新霉素 R 氯霉素 S氨苄青霉素 S 痢特灵 R关孢唑啉 S 复方新诺明 R头孢呋新 S 氟哌酸 R | 丁胺卡那霉素 R 四环素 S庆大霉素 R 红霉素 S链霉素 R 多粘菌素B R新霉素 R 氯霉素 S氨苄青霉素 S 痢特灵 R关孢唑啉 S 复方新诺明 R头孢呋新 S 氟哌酸 R |
毒性试验 | 小鼠腹腔注射1.0×109CFU活菌后,小鼠健存,体重增加。 | |
代谢产物有机酸测定 | 乳酸0.5331%乙酸0.0796% | 乳酸0.5482%乙酸0.0600% |
G+CMol% | 39.76 | 39.76 |
检查项目 | 9403 | 9405 |
生长特性 | (1)需氧或厌氧环境中均可生长(2)在MRS琼脂上生长为浅灰黄色、圆形、突起光滑菌落1-2mm大小。 | (1)需氧或厌氧环境中均可生长(2)在MRS琼脂上生长为浅淡黄色、中央突起圆形菌落约0.5-1mm大小。 |
染色镜检 | 革兰氏染色阳性菌体呈短杆形,约0.3-0.5μm×1-1.5μm。 | 革兰氏染色阳性菌体呈短杆形,约0.5-0.8μm×1-2.5μm |
生化反应 | 阿木鼠核葡甘果半蔗麦拉 李 萄露 乳 芽伯糖糖糖糖糖糖糖糖糖糖- - ± + + + + + + + | 阿木鼠核葡甘果半蔗麦拉 李 萄露 乳 芽伯糖糖糖糖糖糖糖糖糖糖+ - + + + + + + + + |
纤乳蕈蜜棉松 可淀 甘山七维 二子三 溶 露梨叶二 糖糖糖 性粉 醇醇苷糖糖糖+ + + - - + - + + + | 纤乳蕈蜜棉松可淀甘山七维 二子三溶 露梨叶二 糖糖糖性粉醇醇苷糖糖糖+ - + + - + - + + + | |
水明 硝还 石触杨胶 酸 蕊素液 盐原 牛化 奶酶+ - - + - | 水明硝还牛触杨胶酸 奶素液盐原凝化 固酶+ - - + - | |
药敏试验 | 丁胺卡那霉素 R 四环素 S庆大霉素 S 红霉素 S链霉素 S 多粘菌素B R新霉素 R 氯霉素 S氨苄青霉素 S 痢特灵 R关孢唑啉 S 复方新诺明 R头孢呋新 S 氟哌酸 R | 丁胺卡那霉素 R 四环素 S庆大霉素 R 红霉素 S链霉素 R 多粘菌素B R新霉素 R 氯霉素 S氨苄青霉素 S 痢特灵 R关孢唑啉 S 复方新诺明 S头孢呋新 S 氟哌酸 R |
代谢产物有机酸测定 | 乳酸0.9106%乙酸0.0560% | 乳酸0.6884%乙酸0.1115% |
G+CMol% | 41.84 | 42.88 |
VEC编号 | 粘附细菌数(个/VEC) | VEC编号 | 粘附细菌数(个/VEC) | VEC编号 | 粘附细菌数(个/VEC) |
1 | 132 | 18 | 92 | 35 | 85 |
2 | 113 | 19 | 120 | 36 | 123 |
3 | 74 | 20 | 89 | 37 | 144 |
4 | 149 | 21 | 65 | 38 | 131 |
5 | 186 | 22 | 78 | 39 | 156 |
6 | 118 | 23 | 158 | 40 | 98 |
7 | 111 | 24 | 75 | 41 | 143 |
8 | 63 | 25 | 126 | 42 | 125 |
9 | 84 | 26 | 118 | 43 | 95 |
10 | 89 | 27 | 109 | 44 | 194 |
11 | 94 | 28 | 138 | 45 | 88 |
12 | 118 | 29 | 80 | 46 | 155 |
13 | 119 | 30 | 128 | 47 | 178 |
14 | 125 | 31 | 74 | 48 | 122 |
15 | 90 | 32 | 77 | 49 | 167 |
16 | 120 | 33 | 50 | 50 | 133 |
17 | 129 | 34 | 62 | X±S | 113.8±33.69 |
菌株 | 大肠杆菌44113粘附数/VEC(X±S) | 白色念珠菌10231粘附数/VEC(X±S) | 统计处理 |
大肠杆菌44113 | 180.7±252.20 | P<0.01 | |
大肠杆菌44113+嗜酸乳杆菌SL9404 | 134.18±40.63 | ||
白色念珠菌10231 | 29.24±8.85 | 0.01<P<0.05 | |
白色念珠菌10231+嗜酸乳杆菌SL9404 | 24.40±11.36 |
组别 | 不同培养时间的活菌数(CFU/ml)Log值 | ||||||
0小时 | 12小时 | 24小时 | 48小时 | 72小时 | 96小时 | ||
试验组 | SL9404+***29403 | 5.91653.3979 | 8.35023.8692 | 8.8209<1 | 8.4983<1 | 8.0253<1 | |
SL9404+大肠杆菌44113 | 5.91653.7782 | 8.25778.8727 | 8.83958.7404 | 8.9004<5 | 8.7308<1 | ||
SL9404+白色念珠菌10231 | 5.91653.7782 | 8.32017.6821 | 8.57757.8420 | 8.77457.7474 | 8.80287.8921 | 8.75597.9731 | |
对照组 | ***29403 | 3.3979 | 3.8865 | 3.6990 | <1 | <1 | |
大肠杆菌44113 | 3.7782 | 8.8882 | 8.8176 | 8.8987 | 8.4409 | ||
白色念珠菌10231 | 3.7782 | 7.8481 | 8.1614 | 8.1903 | 8.4314 | 8.2041 | |
嗜酸乳杆菌SL9404 | 5.9165 | 8.4100 | 8.7752 | 8.2455 | 7.8722 | 7.1303 |
冻干菌粉 | 100mg |
微晶纤维素 | 500mg |
乳糖 | 320mg |
羧甲基淀粉钠 | 50mg |
硬脂酸镁 | 20mg |
胶态化二氧化硅 | 10mg |
冻干菌粉 | 100mg |
酒石酸 | 400mg |
碳酸氢钠 | 80mg |
碳酸钙 | 60mg |
微晶纤维素 | 200mg |
乳糖 | 120mg |
胶态化二氧化硅 | 10mg |
硬脂酸镁 | 20mg |
羟丙甲纤维素 | 10mg |
冻干菌粉 | 500mg(于双铝箔小包装袋中) |
无菌生理盐水 | 10ml(于小塑料瓶) |
冻干菌粉 | 500mg |
羊毛脂 | 1g |
凡士林 | 1g |
胶态化二氧化硅 | 2.5g |
冻干菌粉 | 100mg |
PVP | 500mg |
无菌生理盐水 | 10 |
二氧化碳 | 适量 |
Claims (3)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB001254693A CN1234373C (zh) | 2000-09-28 | 2000-09-28 | 含嗜酸乳杆菌的药物制剂及制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB001254693A CN1234373C (zh) | 2000-09-28 | 2000-09-28 | 含嗜酸乳杆菌的药物制剂及制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1345589A CN1345589A (zh) | 2002-04-24 |
CN1234373C true CN1234373C (zh) | 2006-01-04 |
Family
ID=4591257
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB001254693A Expired - Fee Related CN1234373C (zh) | 2000-09-28 | 2000-09-28 | 含嗜酸乳杆菌的药物制剂及制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN1234373C (zh) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SK286263B6 (sk) * | 2004-07-16 | 2008-06-06 | Výskumný Ústav Chemických Vlákien, A. S. | Koncentrát aditíva na termostabilizáciu polyamidových vlákien |
IT1403661B1 (it) | 2011-01-28 | 2013-10-31 | Probiotical Spa | Composizione effervescente in forma solida per uso in applicazioni vaginali per il trattamento di infezioni vaginali. |
ITMI20110792A1 (it) | 2011-05-09 | 2012-11-10 | Probiotical Spa | Ceppi di batteri appartenenti al genere bifidobacterium per uso nel trattamento della ipercolesterolemia. |
ITMI20110793A1 (it) | 2011-05-09 | 2012-11-10 | Probiotical Spa | Ceppi di batteri probiotici e composizione sinbiotica contenente gli stessi destinata alla alimentazione dei neonati. |
ITMI20110791A1 (it) | 2011-05-09 | 2012-11-10 | Probiotical Spa | Ceppi di batteri in grado di metabolizzare gli ossalati. |
ITRM20110477A1 (it) | 2011-09-09 | 2013-03-10 | Giovanni Mogna | Composizione comprendente n-acetilcisteina e/o lisozima microincapsulato gastroprotetto in associazione con batteri probiotici in grado di ripristinare l'effetto barriera proprio dello stomaco che viene perso durante il trattamento farmacologico dell |
ITMI20111718A1 (it) | 2011-09-23 | 2013-03-24 | Probiotical Spa | Un materiale impermeabile alla umidita e allo ossigeno per confezionare prodotti dietetici, cosmetici e specialita medicinali. |
ITMI20130793A1 (it) | 2013-05-14 | 2014-11-15 | Probiotical Spa | Composizione comprendente batteri lattici per uso nel trattamento preventivo e/o curativo delle cistiti ricorrenti. |
CN103695442B (zh) * | 2013-12-13 | 2016-01-20 | 上海市农业科学院 | 一种源于嗜酸乳杆菌的nfsai基因及其制备方法和应用 |
CN107714672B (zh) * | 2017-09-11 | 2019-08-06 | 广州市微生物研究所 | 一种妇用***活性益生菌凝胶包囊及其制备方法 |
CN114591875B (zh) * | 2022-05-07 | 2022-07-29 | 微康益生菌(苏州)股份有限公司 | 一种改善***环境的嗜酸乳杆菌la88及其培养方法与应用 |
-
2000
- 2000-09-28 CN CNB001254693A patent/CN1234373C/zh not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
CN1345589A (zh) | 2002-04-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11980660B2 (en) | Edible vaccination against microbial pathogens | |
CN1308436C (zh) | 作为人体***中的益生微生物的乳酸产生细菌 | |
TWI652343B (zh) | 一種捲曲乳桿菌(lactobacillus crispatus)及其應用 | |
TWI627276B (zh) | 新穎之卷曲乳酸桿菌(lactobacillus crispatus)菌株 | |
CN1342196A (zh) | 用于治疗炎性疾病的双歧杆菌 | |
CN1234373C (zh) | 含嗜酸乳杆菌的药物制剂及制备方法 | |
Huicab-Pech et al. | Pathogenic bacteria in Oreochromis niloticus var. Stirling tilapia culture | |
CN1057563C (zh) | 一种枯草芽孢杆菌菌株及其应用 | |
CN113249255B (zh) | 一种防控禽肠炎的枯草芽孢杆菌及其应用 | |
CN116083273B (zh) | 一株植物乳杆菌NHE-LpE15及应用 | |
WO2016046706A1 (en) | Probiotic fermented feed additives | |
CN115287224A (zh) | 一株改善本源动物肠道微生物发育的牦牛源罗伊氏乳杆菌及其应用 | |
KR102130646B1 (ko) | 신규한 락토바실러스 살리바리우스 및 이를 유효성분으로 포함하는 양식 어류 및 갑각류용 사료첨가제 | |
CN109652334A (zh) | 一种微生物复合菌剂及其制备方法和应用 | |
CN109486732A (zh) | 一种长双歧杆菌及其应用 | |
CN116004430B (zh) | 一株植物乳杆菌NHE-LpE9及应用 | |
CN1059235C (zh) | 一种枯草芽孢杆菌活菌制剂及其制做方法 | |
CN101067120A (zh) | 粪肠球菌cms-h001及其应用 | |
CN1391905A (zh) | 一种治疗肠道疾病的微生物制剂 | |
CN115851494A (zh) | 一株植物乳杆菌NHE-LpE5及应用 | |
JP2006158396A (ja) | サボテンの乳酸菌発酵物の製造のための新規な乳酸菌菌株及びこれを用いたサボテン発酵物の製造方法 | |
CN1546064A (zh) | 一种防治鸡白痢的冻干微生态制剂 | |
CN109517765A (zh) | 一种粪链球菌及其应用 | |
CN112940998B (zh) | 一种用于预防细菌性疾病的菌株及应用 | |
CN113604400B (zh) | 具有预防或治疗糖尿病作用的新型乳杆菌yuyingw |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C06 | Publication | ||
PB01 | Publication | ||
ASS | Succession or assignment of patent right |
Owner name: XINYI PHARMACEUTICAL FACTORY Free format text: FORMER OWNER: SHANGHAI XINYI PHARMACEUTICAL CO., LTD. Effective date: 20040917 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20040917 Address after: 201206 No. 905 Jinqiao Road, Shanghai Applicant after: Sine Pharmaceutical Factory Co., Ltd. Address before: 201206, Jinqiao new Jinqiao Road 905, Shanghai, Pudong Applicant before: Xinyi Pharmaceutic Co., Ltd., Shanghai |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C56 | Change in the name or address of the patentee |
Owner name: SHANGHAI SINE PHARMACEUTICAL FACTORY CO., LTD. Free format text: FORMER NAME: SINE PHARMACY FACTORY |
|
CP03 | Change of name, title or address |
Address after: No. 905 Jinqiao Road, Shanghai, Pudong New Area Patentee after: Shanghai Sine Pharmaceutical Co., Ltd. Address before: No. 905 Jinqiao Road, Shanghai Patentee before: Sine Pharmaceutical Factory Co., Ltd. |
|
C56 | Change in the name or address of the patentee | ||
CP01 | Change in the name or title of a patent holder |
Address after: 201206 Pudong New Area new Jinqiao Road, Shanghai, No. 905 Patentee after: Shanghai Xinyi Pharmaceutical Co. Ltd.. Address before: 201206 Pudong New Area new Jinqiao Road, Shanghai, No. 905 Patentee before: Shanghai Sine Pharmaceutical Co., Ltd. |
|
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20060104 Termination date: 20190928 |
|
CF01 | Termination of patent right due to non-payment of annual fee |